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Abstract
Rationale The stop-signal paradigm measures the ability to
stop a motor response after its execution has been initiated.
Impairmentsininhibitinginappropriatebehaviorandprolonged
stop-signal reaction times (SSRTs) are characteristic of several
psychiatric disorders, most notably attention deficit/hyperactiv-
ity disorder. While there is relative consensus regarding the
anatomical substrates of behavioral inhibition, the neurochem-
ical imbalance responsible for the deficits in stopping displayed
by impulsive individuals is still a matter of debate.
Objective The aim of this study was to investigate the
effects of manipulating brain monoamine levels on stop
task parameters.
Methods Lister-hooded rats were trained on the rodent
version of the stop-signal task and administered different
monoamine transporter inhibitors: citalopram, which selec-
tively blocks the serotonin transporter; atomoxetine, which
selectively blocks the noradrenaline transporter; and GBR-
12909, which selectively blocks the dopamine transporter
(DAT), and the alpha-2 adrenergic agonist guanfacine.
Results Atomoxetine speeded SSRTand increased accuracy
for go-trials. Citalopram slowed go reaction time and
decreased go accuracy at the highest dose (1 mg/kg).
GBR-12909 speeded go reaction time and impaired both go
and stop accuracy. Guanfacine negatively modulated all
principal stop and go measures at the highest dose used
(0.3 mg/kg).
Conclusions The results suggest that atomoxetine exerts its
beneficial effects on SSRT via its action on noradrenaline
re-uptake, as the specific DAT blocker GBR-12909 and
serotonin reuptake blockade had only minor effects on
SSRT. The speeding of the go reaction time by dopamine
reuptake blockade is consistent with the hypothesis that the
hypothetical stop and go processes are modulated by
distinct monoaminergic systems.
Keywords Stop-signaltask.Responseinhibition.SSRT.
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Introduction
Behavioral inhibition is one of the most studied constructs
in psychopathology and is known to be dysfunctional in a
wide range of psychiatric conditions characterized by
impulsive behavior such as personality disorders, mania,
substance abuse and attention deficit/hyperactivity disorder
(ADHD) (Barkley 1997; Groman et al. 2007; Moeller et al.
2001). The stop-signal paradigm (Logan 1994; Logan et al.
1984) measures a specific kind of executive inhibition often
referred to as motor or behavioral inhibition and is
sufficiently sensitive to differentiate impulsive individuals
from the normal population (Oosterlaan et al. 1998; Rubia
et al. 1998). Investigation of the neural and neurochemical
mechanisms necessary for inhibitory control, however,
requires the use of a suitable analog of the stop-signal task
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Of the main neuromodulatory systems of the brain,
serotonin (5-HT), dopamine (DA), and noradrenaline (NA)
appear to play crucial roles in different forms of behavioral
inhibition (Robbins 2007). A family of proteins known as
cell membrane monoamine transporters, which are targets
for many therapeutic compounds and drugs of abuse,
enable the regulation of extracellular levels of monoamines
(Iversen 2006; Masson et al. 1999). Indeed, the most
widely used drugs in the pharmacotherapy of ADHD (i.e.,
amphetamine, methylphenidate, and recently, atomoxetine)
act on membrane transporters to inhibit the reuptake of
catecholamines (Heal et al. 2008).
While functional neuroimaging studies point to cortico-
striatal circuitry and, more specifically, to the right inferior
frontal gyrus and the striatum as playing an important role
in the mediation of stopping behavior (Aron et al. 2003;
Robbins 2007; Rubia 2002; Semrud-Clikeman et al. 2000;
Vaidya et al. 1998), the neurochemical substrates responsi-
ble for the modulation of the cerebral areas involved in
response inhibition as measured by the stop-signal task
have yet to be precisely defined.
We have recently shown that atomoxetine, a selective
noradrenaline reuptake inhibitor (SNRI), has dose-
dependent, beneficial effects on different forms of impul-
sivity in the rat (Robinson et al. 2008). A key question in
the psychopharmacology of impulsive behavior is whether
these effects are mainly mediated by dopamine, noradren-
aline, or both. In fact, atomoxetine, despite its high
selectivity for the noradrenaline transporter (NET),
increases in vivo extracellular levels of both catechol-
amines in prefrontal cortex (PFC; Bymaster et al. 2002),
in addition to acetylcholine and histamine (Horner et al.
2007; Tzavara et al. 2006). Atomoxetine shares some of
these properties with other drugs used for the treatment of
ADHD such as amphetamine and methylphenidate (Horner
et al. 2007; Tanda et al. 1997; Tzavara et al. 2006), but it
lacks significant dopaminergic modulation in nucleus
accumbens (NAc) and striatum (STR) (Bymaster et al.
2002), which is a characteristic of stimulant drugs. GBR-
12909, instead, is a highly selective inhibitor of the
dopamine transporter (DAT) with little affinity for the
noradrenaline and serotonin (SERT) transporters (Rothman
et al. 2001).
In order to investigate the consequences of independent-
ly blocking 5-HT, NE, and DA transporters on stop task
variables, we tested, in a series of discrete experiments, the
effects of systemic administration of citalopram, atom-
oxetine, and GBR-12909, respectively. To further explore
the effect of modulating noradrenergic tone, we also used
the selective alpha-2 adrenergic agonist guanfacine (Easton
et al. 2006), which has been shown to ameliorate ADHD
symptoms in humans and other animals (Sagvolden 2006;
Scahill et al. 2001; Taylor and Russo 2001) and to regulate
DA and NA neurotransmission in PFC (Devoto et al. 2004).
Comparisons of these drugs may (a) illuminate the precise
mode of action of atomoxetine in its effect on stop-signal
reaction time (SSRT) and (b) test the hypothesis that go
reaction time (GoRT) is independently modulated by
dopamine (Eagle et al. 2007).
An important additional aim of these studies was to
validate the rodent version of the stop task against results
acquired with human subjects in our laboratory (Chamberlain
et al. 2006; Clark et al. 2005;M ü l l e re ta l .2005) and to test
the effect of a broader range of drug doses which is usually
limited, for obvious ethical reasons, in experiments employ-
ing human subjects.
Materials and methods
Subjects
After excluding those rats that were not performing
according to pre-determined criteria (n 33; see below), a
total of 87 male Lister-hooded rats (Charles River, UK) was
used in four different experiments: 26 animals took part in
experiment 1, 24 in experiment 2, 12 in experiment 3, and
25 in experiment 4. For each experiment, their weights
ranged from 350 to 470 g, and the mean age was
approximately 4 months at the start of testing. All subjects
werehousedingroupsoffour,underareversed12:12-hlight–
darkcycle (lights off at07:30)andweretestedduringthe dark
phase of this cycle. In all four experiments, rats were
approximately85%oftheweightsoffree-feedingindividuals.
Weight gain was restricted by feeding with a total of 15–20 g
of food per day (reinforcer pellets during the task plus
standard laboratory chow). Food restriction started at least
1 week before the beginning of training.
Water was freely available except during test sessions.
All experiments were conducted in accordance with the
United Kingdom Animals (Scientific Procedures) Act,
1986.
Apparatus
All sessions were performed in six operant conditioning
chambers (Med Associates, VT, USA). Each experimental
chamber had two retractable levers positioned 70 mm
above the floor and 80 mm to either side of a central food
well. A pellet dispenser delivered 45-mg Noyes Formula P
pellets (Sandown Scientific, Middlesex, UK) into the food
well, where head entries were monitored with an infrared
detector. A houselight in the roof of the chamber remained
on throughout the session with the exception of time-out
274 Psychopharmacology (2009) 205:273–283(TO, i.e., 5s of darkness) periods. A central light, positioned
above the food well, signaled reinforcement delivery and/or
that a nose-poke was required to start a new trial. Lights
above the left and right levers signaled presentation of the
corresponding lever. A 4,500-Hz Sonalert tone generator
(Med Associates) was mounted high on the wall opposite to
the levers and food well. Control of the experimental
chambers and on-line data collection were conducted using
the Whisker control system (Cardinal and Aitken 2001) and
a custom software written in C++ by DME and JMC
England.
Stop task
All rats were trained to perform the stop task following a
training program that has been previously described in
detail (Eagle and Robbins 2003). During training and
between-drug baseline sessions, rats received one 20-min
session per day, with a maximum of 200 trials. In all
sessions, trials were initiated with a nose-poke to the food
well, after which the left lever and left light were presented.
A press on the left lever resulted in the right lever and right
light being presented, and the left lever and left light were
withdrawn/extinguished. Rats were trained to perform a
rapid operant response from left lever to right lever—the go
response. Response speed was maintained by limiting the
time for which the right lever was presented—the limited
hold (LH; ranging from 0.8 to 1.5 s in experiments 1 and 4
and 1.1 s for all the animals in experiments 2 and 3,
maintained at a constant value for each rat throughout the
study). During go-trials, rats were rewarded with a pellet
delivered to the central food well for pressing the right
lever, but received a TO if they failed to press the right
lever within the LH period. On 20% of the trials, the stop-
trials, a tone (40 ms, 4,500 Hz, ~80 dB) was presented at a
predetermined time between the left and right lever presses.
Stop-trials were presented randomly within the session to
discourage the rats from anticipating presentation of the
stop-signal. On stop-trials, the rats were required to initiate
the same operant response as on go-trials but, after hearing
the stop-signal, to refrain from pressing the right lever. Rats
were required to withhold from responding for the LH
period, after which they were rewarded with a pellet. An
incorrect response in a stop-trial—which was a press on the
right lever—resulted in a TO. Following initial training, rats
received 20-min baseline sessions, during which, the stop-
signal was presented as the left lever was pressed (i.e., with
no delay between the onset of the go response and the
presentation of the stop-signal; zero delay—ZD). Mean go-
trial reaction time (mRT) and stop-signal delays (SSDs) for
each rat were obtained across three ZD sessions. Over the
following five sessions, individual rat inhibition functions
(IF) were generated (see Fig. 1 for a representative IF
averaged across subjects: n=26), with SSDs presented in a
randomized order from the following set: SSD = mRT–
600 ms; mRT–500 ms; mRT–400 ms; mRT–300 ms; mRT–
200 ms. Prior to drug testing, rats were removed from the
study if their inhibition functions showed an increase
(rather than a decrease) in stop-trial accuracy across
increasingly difficult delays or if they were slowing down
their GoRT waiting for the stop-signal to occur. A closer
analysis of the performance of the remaining rats revealed
that they were performing the task according to the
assumptions of the “Race” model (see Logan 1994). In
particular, the model assumes that go and stop processes are
independent from each other and that the SSDs bias the
race in favor of one or the other process.
On days when SSRT was calculated (SSRT sessions for
drug-testing days and baselines), rats performed one session
per day that was divided into 3×10-min test periods, with a
maximum of 80 trials per period. Data from the first period at
ZD were usedto calculatemRT foreach rat, and this mRTwas
used to set the SSDs in the subsequent two periods, presenting
the stop signals at mRT–500 ms and at mRT–300 ms. SSRT
was estimated from the data of the last two periods. Twenty
percent of trials in each test period were randomly determined
to be stop-trials (16 trials per 80-trial period). During drug
testing, drugs were given on Tuesdays and Fridays, with
baseline sessions on Mondays and Thursdays.
Drug administration
All rats were tested for baseline performance prior to the
beginning of the drug treatment. They were then divided
into as many groups as the number of drug doses used in
the specific experiment and matched for SSRT and mRT.
All groups received the drug according to a fully
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Fig. 1 Representative inhibition function obtained by plotting the
stop-signal delays against the probability of successful response
inhibition. ZD zero delay
Psychopharmacology (2009) 205:273–283 275randomized Latin-square design. On every test day, the
drugs were freshly dissolved and administered by subcuta-
neous (s.c.) injections at 1 ml/kg except in experiment 3
(see below). In experiment 1, citalopram hydrobromide
(four doses, 0.03, 0.1, 0.3, and 1 mg/kg, plus vehicle;
Tocris, Bristol, UK) was dissolved in 0.01 M phosphate
buffer saline (PBS) and administered 30 min before the test
sessions. In experiment 2, atomoxetine (one dose, 1 mg/kg,
plus vehicle; Eli Lilly & Co Ltd) was dissolved in PBS and
administered 30 min before test sessions. In experiment 3,
GBR-12909 (Tocris) was dissolved in distilled water and
administered s.c. at 1 ml/kg for the first part of the
experiment (four doses, 0.1, 0.3, 1, and 3 mg/kg, plus
vehicle), by intraperitoneal (i.p.) administration at 2 ml/kg
for the second part (one dose, 5 mg/kg, plus vehicle) and at
4 ml/kg i.p. for the third part (1 dose, 10 mg/kg, plus
vehicle). GBR-12909 was always administered 30 min
before tests sessions. In experiment 4, guanfacine (kindly
provided by Pfizer Inc., four doses, 0.01, 0.03, 0.1, and
0.3 mg/kg, plus vehicle) was dissolved in vehicle contain-
ing 1% cremophor and 0.5% methylcellulose and adminis-
tered 1 h before the test commenced. On the first day of
testing a group of rats received 1 mg/kg of guanfacine, but
this dose was subsequently discontinued due to excessive
sedation. Drug doses and administration modalities were
chosen based on published and unpublished reports
showing in vivo efficacy in functional neurochemistry
assays (e.g., Bymaster et al. 2002; Tanda et al. 1997)
During the time between the administration of the
compound and the beginning of the task, animals were
singly housed in holding cages and left undisturbed in a
quiet room.
Data analysis
Data are presented for drug doses plus vehicle. Collected data
were compiled in a relational database (Microsoft Access
2002) and analyzed using SPSS 12.0.1 (SPSS, Chicago, IL,
USA). Graphs were plotted using SigmaPlot 8.0 (SPSS).
Behavioral data were subjected to repeated-measures
analyses of variance (ANOVAs) using a general linear
model. All tests of significance were performed at α=0.05
and models were full factorial. Homogeneity of variance
was verified using Levene’s test. For repeated-measured
analyses, Mauchly’s test of sphericity was applied and the
degrees of freedom corrected to more conservative values
using the Huynh–Feldt epsilon ε for any terms involving
factors in which the sphericity assumption was violated.
Corrected degrees of freedom are presented rounded to the
nearest integer. Following repeated-measures analyses,
pairwise comparisons were performed, with α adjusted
using Sidak’sm e t h o dα′=1−(1−α)
1/c,w h e r ec is the
number of within-experiment analyses (Howell 1997).
For each drug, the following variables have been
analyzed: SSRT, mRT, stop accuracy, and go accuracy.
mRT represents the mean of reaction times (RTs) during
trials in which no stop-signal was presented. Stop and go
accuracy represent the proportion of successful stop and go
trials, respectively, and are expressed as percentage.
SSRTs were estimated using the protocol described in
Logan (1994). GoRTs were rank ordered. We selected the nth
RT from the ranked list of GoRTs at a specific delay, where n
was obtained by multiplying the number of GoRTs in the
distribution by the probability of responding on stop-trials at
that delay. This gave an estimate of the time at which the
stopping process finished, relative to the onset of the go-
signal. To estimate SSRT (the time at which stopping finished
relative to the stop-signal), the SSD was subtracted from this
finishing time value. SSRTs from the second test period
(mRT-500) and the third (mRT-300) were then averaged to
obtain a single value (estimated SSRT) for each rat.
The probability of inhibiting the response on stop-trials
was corrected for the presence of omission errors (trials in
which the rat failed to respond for a reason unrelated to a
slowing of SSRT, such as inattention or distraction)
following a procedure described fully in Eagle and Robbins
(2003) and is presented as “adjusted stop accuracy”.
Results
Experiment 1: effects of citalopram administration
Repeated-measures analyses of variance (ANOVA) failed to
reveal a main effect of citalopram doses tested on estimated
SSRT (Fig. 2, upper left panel). A main effect of citalopram
was found on mRT (F(4,100)=5.2, p<0.05). Pairwise
comparisons revealed a slowing effect of the highest dose
tested (1 mg/kg) compared to vehicle (Fig. 2, upper right
panel). There were no effects of any dose on the adjusted
stop accuracy (Fig. 2, lower left panel). Citalopram
significantly affected go-trial accuracy (Fig. 2, lower right
panel) at 1 mg/kg, (F(4, 100)=4.6, p<0.05); simple effects
analysis revealed that, at this dose, go-trial accuracy was
significantly lower compared with all other doses used.
Experiment 2: effects of a single dose of atomoxetine
Atomoxetine (1 mg/kg; Fig. 3), as previously reported in a
fuller dose–response analysis (Robinson et al. 2008),
significantly decreased estimated SSRT as compared
to vehicle performance (F(1, 23)=6.99, p≤0.01). Atomoxe-
tine significantly slowed the mRT (F(1, 23)=19.8, p<
0.001). Go-trial accuracy was increased at the dose tested
(F(1, 23)=5.65, p≤0.02) and there was a trend toward an
improvement for the adjusted stop accuracy.
276 Psychopharmacology (2009) 205:273–283Experiment 3: effects of GBR-12909 administration
Subcutaneous administration of GBR-12909 had no signif-
icant effect on any stop task parameter with the first set of
doses used (data not shown). Five milligrams per kilogram
of the same drug (Fig. 4, upper panel) administered via i.p.
injection speeded mRT (F(1, 11)=5.527, p<0.05), but not
SSRT. At this dose, adjusted stop accuracy (F(1, 11)=
7.694, p<0.05), but not go-trial accuracy, was significantly
decreased. Ten milligrams per kilogram (Fig. 4, lower
panel) did not have any effect on mRT. SSRT was also not
influenced by GBR-12909, and ANOVA revealed a
significant decrease in both stop (F(1, 11)=5.826, p<
0.05) and go-trial (F(1, 11)=6.332, p<0.05) accuracy.
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Fig. 3 Effects of atomoxetine (1 mg/kg) on estimated SSRT, mRT, adjusted stop accuracy, and go accuracy. Atomoxetine improved stop task
performance. *p<0.05, Drug vs. Veh; n=24)
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Fig. 2 Citalopram had no effect
on estimated SSRT (upper left)
and adjusted stop-trial accuracy
(lower left). mRT was signifi-
cantly slower at 1 mg/kg (upper
right) and the same dose signif-
icantly decreased go-trial accu-
racy (lower right). *p<0.05 vs.
vehicle; n=26
Psychopharmacology (2009) 205:273–283 277Experiment 4: effects of guanfacine administration
Repeated-measures analyses of variance revealed a signif-
icant main effect of guanfacine treatment on estimated
SSRT (Fig. 5, upper left; F(4, 96)=12.4, p<0.001).
Pairwise tests showed that only 0.3 mg/kg significantly
slowed SSRT compared to all other doses.
There was a main effect of guanfacine on mRT (Fig. 5,
upper right; F(4, 64)=20.02, p<0.001). More specifically,
pairwise comparisons showed a slower mRTat higher doses
compared to vehicle (0 vs. 0.1 mg/kg, p<0.02; 0 vs.
0.3 mg/kg, p<0.001). Guanfacine decreased both adjusted
stop and go-trial accuracy (Fig. 5, lower left and right; go
accuracy: F(3, 52)=32.2, p<0.001; adjusted stop accuracy:
F(4, 68)=20.4, p<0.001). In both cases, only 0.3 mg/kg
was significantly different from vehicle.
Discussion
We have replicated recent findings of speeding effects of
the SNRI atomoxetine on the SSRT measure of behavioral
inhibition in humans (Chamberlain et al. 2006) and rats
(Robinson et al. 2008). Blocking DA transporter by GBR-
12909 administration speeded mRT at the dose of 5 mg/kg,
but SERT blockade and guanfacine administration had only
minor effects on the general performance.
These results suggest that (a) atomoxetine may exert its
effects on SSRT via NA rather than DA reuptake blockade;
(b) there may be dissociable effects of central DA and NA
mechanisms on hypothetical “go” and “stop” processes,
respectively; and (c) blockade of serotonin reuptake over a
wide range of doses failed to affect SSRT, congruent with
human data (Chamberlain et al. 2006).
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Fig. 4 Effects of higher doses of GBR-12909 administered by i.p. route. Five milligram per kilogram speeded reaction time and impaired stop accuracy
(upper panel); 10 mg/kg impaired both stop and go accuracy with no effects on reaction times (lower panel). *p<0.05, Drug vs. Veh; n=12)
278 Psychopharmacology (2009) 205:273–283According to the present results, a study by Overtoom et
al. (2003), found that administration of the tricyclic
antidepressant desipramine speeded SSRTs in children with
ADHD. The authors proposed that the beneficial effects
might have been caused by the modulation of 5-HT levels
by desipramine, which blocks NET like atomoxetine, but
also inhibits the 5-HT transporter (Richelson and Pfenning
1984; Rothman et al. 2001), although to a lesser extent. In
the present study, blocking 5-HT reuptake by citalopram
administration did not improve stopping performance in
rats, but NET blockade with atomoxetine did. This result is
consistent with what has been found in normal human
subjects (Chamberlain et al. 2006) and broadens the range
of citalopram doses tested, though revealing significant
effects only on secondary performance variables. Go-trial
accuracy was decreased and mRT increased with 1 mg/kg
of citalopram, probably because of the mild sedative effects
of the drug. Considering the evidence from recent experi-
ments in humans with acute tryptophan depletion (Clark et
al.2005)—which acutely decreases central 5-HTsynthesis—
and global 5-HT depletion in animals (Eagle et al. 2009),
that did not affect stopping performance, the present results
support the apparent lack of effect of modulating 5-HT
transmission on SSRT. Serotonergic neurotransmission has
been reported to play a prominent role in a different kind of
inhibition, namely, the capacity to withhold over time a
response to affectively charged stimuli and to delay
gratification (Eagle et al. 2009;H a r r i s o ne ta l .1997, 1999;
Soubrié 1986; Wogar et al. 1993), and thus be more
implicated in cognitive—rather than motor—inhibition.
Nevertheless, also due to a long-standing link between
5-HT and behavioral inhibition (Evenden 1999), opposite
roles of different serotonergic receptors on measures of
impulsivity (Carli et al. 2006; Winstanley et al. 2004)a n da
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Fig. 5 Effects of guanfacine on estimated SSRT, mRT, and stop and go accuracies. Both reaction times were significantly slowed by the highest
dose tested. Go and stop accuracies were markedly decreased at 0.3 mg/kg. *p<0.001 vs. vehicle; n=25)
Psychopharmacology (2009) 205:273–283 279possible association between SSRT and a genetic marker of
the human neuronal tryptophan hydroxylase-2 (the rate-
limiting enzyme for serotonin biosynthesis; Stoltenberg et al.
2006), 5-HT involvement in stopping deserves further
investigation and a study employing subchronic or chronic
administration of SSRIs is still lacking.
We recently demonstrated that atomoxetine dose-
dependently speeds up SSRT and that this effect was not
dependent on animals’ baseline performance (Robinson et
al. 2008). In the present study, we also obtained a
significant improvement in go accuracy and a slowing of
mRT at 1 mg/kg. Both effects were present as trends in the
study by Robinson et al. (2008), though they did not reach
significance. This could be due to the slightly different and
more stringent parameters used in this study (i.e., shorter
LH) or to the fact that more subjects have been used in the
present study, which provided greater statistical power.
Moreover, a different route of drug administration (i.p. in
the previous report vs. s.c. in the present study) could have
influenced the drug’s absorption rate and distribution. The
fact that atomoxetine slowed mRT cannot, of course,
explain the speeding effect on SSRT. In fact, even though
a slower GoRT can facilitate stopping performance, our
procedure takes into account such slowing effects and
allows setting delays based on the actual GoRT after drug
administration. A longer GoRT is consistent with the
increase in alpha-2 inhibitory autoreceptor stimulation in
the locus coeruleus as a consequence of heightened NA
levels (De Sarro et al. 1987), although, at low doses, it
becomes apparent only under very challenging task
demands. The beneficial effect on go accuracy is more
difficult to explain. One possibility is that atomoxetine
makes animals less prone to interrupt the chain of actions
required to complete a go response, and thus better at
inhibiting premature responses to the food magazine in the
middle of the sequence, which, during go-trials, would
be likely to cause the rat to exceed the LH and, hence,
commit a go-error. On the other hand, atomoxetine could
improve the animal’s capacity for sustained attention
over many trials and thus enable effective application of
task contingencies.
GBR-12909 speeded mRT at 5 mg/kg, decreased go
accuracy at 10 mg/kg, and caused a marked decrease in
stop accuracy at both doses. The observed increase in the
speed of mRT after GBR-12909 administration is consistent
with its DA-enhancing effect in DAT-rich subcortical areas
like the striatum. In fact, in the prefrontal cortex, DAT
distribution is very sparse (Sesack et al. 1998) and most
extracellular DA is transported inside the neuron terminals
by NET (Carboni et al. 1990). The apparent general
disruption of subjects’ performance in this study caused
by a selective dopaminergic agent like GBR-12909 seems
in contrast with the efficacy of psychostimulants in treating
ADHD and speeding SSRT (e.g., Tannock et al. 1989). One
possibility is that the doses that caused such effects (5 and
10 mg/kg) were too high and, hence, at the right end of the
“inverted U” shaped curve which is a typical dose–response
curve for many behavioral effects elicited by catecholamin-
ergic manipulations (Arnsten and Li 2005; Robbins 2000;
Williams and Goldman-Rakic 1995; Zahrt et al. 1997). In
the first part of the experiment, we used low doses of GBR-
12909 delivered by subcutaneous route of administration
that did not cause any appreciable effect on stop task
variables. The two additional highest doses were then
delivered intraperitoneally probably allowing for a more
rapid absorption of the drug and a more potent effect on
DA release (Pozzi et al. 1994; Tanda et al. 1997) which
disrupted rats’ performance. More likely, differences in the
mechanisms of action between commonly prescribed
ADHD drugs and GBR-12909 can explain the results
obtained. Compared to amphetamine and methylphenidate,
GBR-12909 has the lowest affinity for NET and the highest
for DAT (Richelson and Pfenning 1984; Rothman et al.
2001). Consequently, GBR-12909 causes only less than a
twofold increase in the extracellular concentration of DA in
medial PFC (Mazei et al. 2002; Tanda et al. 1997) due to
the paucity of DAT sites in this area (Sesack et al. 1998;
Soucy et al. 1997), but dramatically increases DA—like
other psychostimulants—in DAT-rich subcortical areas
(Tanda et al. 1997). On the contrary, blocking NET with
atomoxetine increases DA—as well as NE—in mPFC, but
not in the striatum (Bymaster et al. 2002). Half-way
between selective NET and DAT blockers, amphetamine
and methylphenidate evoke a larger increase of extracellular
DA in PFC than in striatal areas (Bymaster et al. 2002;
Tanda et al. 1997).
Guanfacine, a selective alpha-2 adrenergic receptor
agonist, has been proposed as a potential treatment for
ADHD and as a useful alternative to psychostimulant
medication (Scahill et al. 2001; Taylor and Russo 2001).
Guanfacine is known to have beneficial effects on working
memory and attentional functions (Arnsten and Li 2005),
but imbalances in dopaminergic or noradrenergic function
may mediate the efficacy of low doses of this drug (Arnsten
et al. 1988; Franowicz and Arnsten 1998). For example,
guanfacine failed to improve behavioral performance in the
absence of any induced or pre-existing impairment
(Birnbaum et al. 2000). On the other hand, in other studies,
alpha-2 adrenoceptor agonist administration had deleterious
consequences on attention (Smith and Nutt 1996) and target
detection (Coull et al. 2004). Guanfacine, like the other
drugs used in the present report, had no differential effects
in fast or slow stoppers (separated by median split of the
sample (see Eagle et al. 2007); data not shown) suggesting
that the effects found are similar in both “normal” and
behavioral impaired animals.
280 Psychopharmacology (2009) 205:273–283In our study, guanfacine significantly prolonged SSRT
and mRT and decreased both stop and go accuracy at the
highest dose tested (0.3 mg/kg). These effects are probably
caused by a general slowing of performance—likely caused
by feedback inhibition of noradrenaline release by pre-
synaptic alpha 2-receptors stimulation (De Sarro et al.
1987; Engberg and Eriksson 1991)—and not by a decrease
in attentional capacity. In the rat version of the task, the
time available to press the right lever is limited and this
causes the slowest part of the GoRT distribution to be
truncated. Stop accuracy is then decreased because it has to
be adjusted for high levels of omissions on go-trials. A
recent study from this laboratory conducted in humans
failed to find improvements by guanfacine on executive and
memory functions in healthy subjects (Müller et al. 2005).
More specifically, in the stop-signal paradigm, 1 mg of
guanfacine slowed mRT but not SSRT (similarly to the
effects of 0.1 mg/kg in the present study), and this effect
was unlikely to have been caused by more frequent
lapses of attention. These results resemble very closely
the effects found in this study on rats. In fact, guanfacine
did not affect the GoRT variance even at the highest dose
used (0.3 mg/kg; data not shown), this measure being known
to reflect fluctuations in attentional processing (Castellanos
and Tannock 2002).
Available data from human subjects are insufficient for
us to draw clear conclusions about the relative roles of DA
and NA in stopping performance. According to the present
results, we can exclude an increase in subcortical extracel-
lular dopamine from being either sufficient or necessary in
ameliorating stopping performance because GBR-12909
failed to speed SSRT or to increase stop accuracy, while
atomoxetine speeded SSRT. Overtoom et al. (2003) found
that L-Dopa administration in ADHD subjects did not alter
performance in the stop-signal task and methylphenidate
speeded reaction times during go-trials only. Apart from
this latter study, where methylphenidate doses were
probably too low to speed SSRT, the beneficial effects of
methylphenidate and other psychostimulant drugs on
stopping performance often appear to critically depend on
neurobiological and behavioral baseline levels (Boonstra et
al. 2005; de Wit et al. 2000; Eagle and Robbins 2003; Eagle
et al. 2007; Feola et al. 2000; Vaidya et al. 1998; Volkow et
al. 1997, 2004).
As a consequence of the paucity of DAT in the PFC,
SNRIs like atomoxetine, despite their high selectivity for
the NA transporter, cause an increase of extracellular DA as
well as NA there (Bymaster et al. 2002; Carboni et al.
1990; Gresch et al. 1995). The lower abuse viability of
SNRI and increased safety in the treatment of ADHD
patients compared to commonly used psychostimulant
drugs has been attributed to their relative lack of effect in
the DA-rich striatum. On the other hand, atomoxetine may
help to exert a prefrontal inhibitory influence on subcortical
regions, including the striatum, via its effects on cortical
catecholamines (Deutch 1992; Zametkin and Rapoport
1987).
In summary, the present data concur with previous results
in humans and rats (e.g., Chamberlain et al. 2006; Eagle et al.
2007; Overtoom et al. 2003; Robinson et al. 2008)
suggesting a dissociation between the neurochemical mod-
ulation of stopping performance by noradrenaline and the
control of go processes by dopaminergic neurotransmission.
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